The European Patent Office (EPO) has granted patent EP3262065B1, titled "Methods and Compositions for Treating Dystroglycanopathy Disorders." This patent, effective March 18, 2026, provides exclusive rights for the use of specific methods and compositions related to the treatment of dystroglycanopathy disorders within the designated European states.

This grant signifies a new intellectual property right in the field of rare disease treatment. Companies involved in the research, development, or commercialization of therapies for dystroglycanopathies within the EU must be aware of this patent to avoid infringement. The patent's scope will dictate the permissible activities related to these treatment methods and compositions.